Etanercept biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 17 Nov 2021
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in Europe (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in USA (SC, Injection)
- 22 Aug 2013 Etanercept biosimilar - Harvest Moon Pharmaceuticals is available for licensing in Latin America, World (http://harvestmoonpharma.com/biosimilar_products)